Research & Development

Ivan Kairatov is a seasoned biopharma expert with a distinguished career in research and development, particularly focusing on how cutting-edge technology reshapes clinical outcomes for rare diseases. Today, we sit down to discuss the recent FDA Priority Review of Enspryng, a potential breakthrough

Ivan Kairatov is a leading figure in biopharmaceutical innovation, bringing years of dedicated research and development experience to the intersection of oncology and the human microbiome. As an expert who has watched the landscape of cancer treatment shift from traditional chemotherapy to the

The long-standing ambition of regenerating damaged myocardial tissue has frequently encountered a formidable barrier that separates laboratory success from widespread clinical application. While the biological potential of stem cells to transform into functional heart muscle is well-documented, the

The integration of sophisticated biotechnology into mechanical engineering has reached a significant milestone as researchers at the University of Basel successfully demonstrated a modular nanorobot capable of autonomous task execution. Rather than relying on the static designs that once limited

Ivan Kairatov is a titan in the biopharmaceutical sector, recognized for his pioneer work in integrating generative artificial intelligence into the traditional drug discovery pipeline. With a career spanning decades in research and development, Kairatov has been a vocal advocate for moving beyond

The clinical landscape of modern oncology has reached a frustrating plateau where certain aggressive malignancies, despite the advent of revolutionary treatments, remain completely invisible to the human immune system. This persistent invisibility characterizes "immune-cold" environments, where the